Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampin for Idiopathic Infantile Hypercalcemia
NCT03384121Phase 1Unknown
- Sponsor
- SickKids
- Start
- Feb 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifampicin in Idiopathic infantile hypercalcemia (IIH), sponsored by SickKids. Primary endpoints: Change in Serum Calcium at 40 weeks, Change in Serum Parathyroid Hormone at 40 weeks and 1 more. Status: unknown.
02
Drugs
rifampicin
03
Conditions
Idiopathic infantile hypercalcemia (IIH)
Beyond the preview
Go deeper on NCT03384121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384121.